9.15
-0.13(-1.40%)
Currency In USD
| Previous Close | 9.28 |
| Open | 9.17 |
| Day High | 9.22 |
| Day Low | 9.1 |
| 52-Week High | 11.78 |
| 52-Week Low | 5.79 |
| Volume | 31,327 |
| Average Volume | 2.13M |
| Market Cap | 1.46B |
| PE | -8.24 |
| EPS | -1.11 |
| Moving Average 50 Days | 8.06 |
| Moving Average 200 Days | 8.47 |
| Change | -0.13 |
If you invested $1000 in Ocular Therapeutix, Inc. (OCUL) 10 years ago, it would be worth $445.04 as of July 01, 2025 at a share price of $9.15. Whereas If you bought $1000 worth of Ocular Therapeutix, Inc. (OCUL) shares 5 years ago, it would be worth $1,109.09 as of July 01, 2025 at a share price of $9.15.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Ocular Therapeutix™ Unveils New Corporate Branding, Reflecting its Transformation to a Retina-Focused Company
GlobeNewswire Inc.
Jun 26, 2025 5:54 PM GMT
The new branding showcases the Company's innovative vision for the future and mission to redefine the retina experienceBEDFORD, Mass., June 26, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a biopharmaceutical company
Ocular Therapeutix™ to Participate in Clinical Trials at the Summit (CTS) 2025
GlobeNewswire Inc.
Jun 16, 2025 11:00 AM GMT
BEDFORD, Mass., June 16, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a fully-integrated biopharmaceutical company committed to redefining the retina experience, today announced participation at Clinical Trials at the
Ocular Therapeutix™ To Close Enrollment This Week for SOL-R, its Second Registrational Trial Evaluating AXPAXLI™ in Wet Age-Related Macular Degeneration
GlobeNewswire Inc.
May 28, 2025 11:00 AM GMT
Enrollment for SOL-R, the largest retinal TKI trial to date, supports randomization of at least 555 subjects SOL-1, Ocular’s first registrational trial in wet AMD, completed randomization in December 2024 and retention remains exceptional as the tria